Drugs / Pylera
last change 3 days ago re-read 2 minutes ago

Pylera

Developed for
Helicobacter pylori infectious disease
Investigated by
Forest Laboratories

Regulatory milestones approvals, filings & regulatory actions · 1 recorded

MilestoneJurisdictionBrandIndicationDateSentence it was read from
Approved US (FDA) PYLERA 2006-09-28 fda.gov

Trials 1 · a red edge is where a trial was stopped

today
US approved 2006
NCT00669955 · Ph 3
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT00669955 Jun 2008 → Jul 2009 Helicobacter pylori infectious disease Forest Laboratories Completed No outcome recorded
Also used as a comparator or background therapy in 2 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 01 trial
Phase 0 NCT05100446 Comparator May → Dec 2021 Helicobacter pylori infectious disease, gastric cancer, gastritis Unidade Local de Saúde do Alto Ave, EPE Unknown No outcome recorded
Phase 41 trial
Phase 4 NCT06200779 Comparator Sep 2025 → Sep 2026 expected Helicobacter pylori infectious disease Manuel Coelho da Rocha Not yet recruiting No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as Pylera ClinicalTrials.gov intervention name — accepted as the source's own label NCT06200779
2

NCT05100446

NCT00669955